We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In his first appearance as HHS Secretary on Capitol Hill, Alex Azar fielded questions Wednesday about the Trump administration’s plans to address the opioid crisis and drug prices. Read More
“This policy helps restore the appropriate role of guidance documents and avoids rulemaking by enforcement,” said Associate Attorney General Rachel Brand. Read More
The submitted data did not rule out the possibility the proposed formulation could result in more abuse via injection than using a conventional oxycodone formulation. Read More
Allergan agreed to pay a class of doctors $13.45 million over claims the company artificially maintained the price of Botox through a deal with a potential competitor. Read More
Leading U.S. opioid manufacturers donated millions of dollars to organizations that doubled as advocacy groups, potentially fueling the opioid epidemic, according to the latest report to emerge from the opioids investigation by Sen. Claire McCaskill (D-Mo.). Read More
Two senators called on the Trump administration to back a bill requiring drugmakers to justify any proposed price increases — invoking the president’s commitment in the State of the Union address to prioritize reducing drug prices. Read More